Spots Global Cancer Trial Database for js001
Every month we try and update this database with for js001 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of JS001 in Participants With Advanced Solid Tumors | NCT02857166 | Solid Tumors | humanized anti-... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) | NCT04523883 | Head and Neck S... | postoperative r... JS001 | 18 Years - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | NCT04250948 | Gastric Cancer Locally Advance... | JS001 Oxaliplatin S1 Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | NCT04250948 | Gastric Cancer Locally Advance... | JS001 Oxaliplatin S1 Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. | NCT03623776 | Efficacy and Sa... | JS001 Pemetrexed Carboplatin Thoracic Surger... | 18 Years - 75 Years | Sun Yat-sen University | |
| Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer | NCT04119622 | Gastric Cancer ... Gastric Cancer ... | Toripalimab oxaliplatin capecitabine | 18 Years - 75 Years | ChineseAMS | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | NCT05297552 | Muscle Invasive... | RC48-ADC JS001 | 18 Years - | RemeGen Co., Ltd. | |
| Newly Emerging Immunotherapy for Pancreatic Cancer Treatment | NCT06370754 | Pancreatic Canc... | JS001 JS004 JS007 JS015 Irinotecan Lipo... 5-Fluorouracil ... Leucovorin (LV) Nab paclitaxel Gemcitabine | 18 Years - 75 Years | Fudan University | |
| Study of JS001 in Participants With Advanced Solid Tumors | NCT02857166 | Solid Tumors | humanized anti-... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | NCT04991506 | Solid Tumor Neoplasms Malignant Tumor | ES102 JS001 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer | NCT03946917 | Colorectal Canc... | JS001 regorafenib tab... | 18 Years - | Sun Yat-sen University | |
| Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) | NCT04523883 | Head and Neck S... | postoperative r... JS001 | 18 Years - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors | NCT04280341 | HER2-Positive S... | RC48-ADC in com... | 18 Years - | Peking University | |
| A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer | NCT04118933 | Colorectal Canc... | JS001 | 18 Years - 75 Years | Fudan University | |
| Newly Emerging Immunotherapy for Pancreatic Cancer Treatment | NCT06370754 | Pancreatic Canc... | JS001 JS004 JS007 JS015 Irinotecan Lipo... 5-Fluorouracil ... Leucovorin (LV) Nab paclitaxel Gemcitabine | 18 Years - 75 Years | Fudan University | |
| Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC | NCT04116918 | NSCLC Stage IV EGFR T790M-nega... Anlotinib JS001 | 18 Months - 75 Years | Shanghai Changzheng Hospital | ||
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | NCT04991506 | Solid Tumor Neoplasms Malignant Tumor | ES102 JS001 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors | NCT02836834 | Lymphoma Lung Cancer | JS001 | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer | NCT04118933 | Colorectal Canc... | JS001 | 18 Years - 75 Years | Fudan University | |
| Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment | NCT04085276 | Triple-Negative... | JS001 Nab-Paclitaxel Placebo Nab-Paclitaxel | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer | NCT04119622 | Gastric Cancer ... Gastric Cancer ... | Toripalimab oxaliplatin capecitabine | 18 Years - 75 Years | ChineseAMS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
